Skip to main content
. 2021 Nov 2;9(1):e1098. doi: 10.1212/NXI.0000000000001098

Figure 2. Clinical Status, NF155 Titers, and sNfL Levels After Rituximab Treatment Induction: Kinetics.

Figure 2

Rituximab treated anti-NF-155 patients with follow-up samples at regular time points show improvement in the mRS scale, a decrease in NF155 titers, and a decrease in sNfL levels starting on the third month of treatment infusion. The line in the center represents the median value, and the whiskers indicate the interquartile range. mRS = modified Rankin Scale; NF155 = neurofascin-155; NF155 = neurofascin-155; sNfL = serum neurofilament light chain.